Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.
Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.
Oishi
Taku
T
Department of Pediatrics, Kochi National Hospital, Kochi, Japan.
Fujieda
Mikiya
M
Shiraishi
Taisuke
T
Ono
Miki
M
Inoue
Kazuo
K
Takahashi
Akiyoshi
A
Ogura
Hideo
H
Wakiguchi
Hiroshi
H
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003323:Coronary Aneurysm / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004351:Drug Resistance; D004452:Echocardiography; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D000069285:Infliximab; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab